EGFR and metastatic neoplasm: This percentage was about the same among patients with metastatic disease at the time of EGFR-TKI treatment initiation [24.1% (21/87)], while it increased to 30.7% (27/88) among evaluable patients with metastatic disease at the time of progression in the first-line setting.